In the Boardroom
Refine Search
Pharmaceutical
Newly-launched obesity company Kailera Therapeutics has announced the appointment of Jamie Coleman as chief commercial officer (CCO). 28 January 2025
Biotechnology
Boston, USA-based biotech Averna Therapeutics (formerly known as Exsilio Therapeutics), revealed yesterday that it has appointed Thomas Barnes as its chief executive (CEO) and director. 28 January 2025
Biotechnology
Swarm Oncology, a biotech developing novel T cell therapies to achieve long-term remission in patients with advanced solid cancers, has emerged from stealth mode and announced the appointment of Martin Olin as chief executive. 27 January 2025
Pharmaceutical
The board of LINK Medical has announced the appointment of Anders Göransson as the new chief executive (CEO) of the Norwegian contract research organization (CRO). 27 January 2025
Pharmaceutical
Neurocrine Biosciences has announced the appointment of Andrew Ratz as senior VP of drug development, supporting the firm’s expanding R&D efforts. 24 January 2025
Biotechnology
Danish biotech Genmab (CPH: GMAB) today announced it has named Leslie Amendola senior vice president and general manager of its US business. 24 January 2025
Biotechnology
Kyverna Therapeutics (Nasdaq: KYTX), a California biotech developing CAR-T therapies for autoimmune diseases, has appointed Naji Gehchan as chief medical officer. 22 January 2025
Biotechnology
Arvinas has announced a change in its commercial leadership, with John Northcott stepping down from his role as chief commercial officer, due to personal reasons. 21 January 2025
Biotechnology
Dutch biotech Pharming Group today announced that its board of directors has nominated Fabrice Chouraqui to become the company’s new executive director and chief executive, succeeding Sijmen de Vries. 21 January 2025
Pharmaceutical
UK clinical-stage specialty pharma firm Actimed Therapeutics has appointed Dr Fabio Dorigotti as chief medical officer (CMO) following the retirement of previous CMO, Dr Frank Misselwitz. 16 January 2025
Pharmaceutical
Boston, USA-based Verastem Oncology today announced the appointment of Matthew Ros as chief operating officer (COO). 15 January 2025
Biotechnology
French immunotherapy company OSE Immunotherapeutics has appointed Dr Sonya Montgomery as chief development officer. She will serve on the OSE executive committee in a strategic move that will enhance the company’s development capabilities. 14 January 2025
Pharmaceutical
French independent pharma company Servier says it has appointed David Lee to its executive committee as executive vice president for the United States, effective January 1, 2025. 13 January 2025
Pharmaceutical
Medicines Discovery Catapult (MDC), the UK government-backed life sciences service dedicated to driving productivity and impact in drug R&D, has strengthened its executive team with the appointment of a chief commercial officer (CCO) and its first managing director (MD). 13 January 2025
Biotechnology
California-based immunology start-up Ouro Medicines, which is developing immune reset therapeutics for people living with chronic immune-mediated diseases, has announced its launch with $120 million in funding. 13 January 2025
Pharmaceutical
Artbio, a radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), has named Margaret Yu its chief medical officer (CMO). 10 January 2025
Biotechnology
German biotech CatalYm has appointed Scott Clarke as chief executive (CEO), noting that he brings over two decades of executive leadership experience in driving company growth, developing products, and shaping and executing transactions in the biopharmaceutical industry. 10 January 2025
Biotechnology
UK-based biotech MitoRx Therapeutics has bolstered its leadership team with the appointment of Lubor Gaal as chief business officer and Stacey Massey as finance director. 9 January 2025
Pharmaceutical
UK headquartered Verdiva Bio Limited today announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. 9 January 2025
Biotechnology
Cambridge, USA-based biotech Sunbird Bio, which is developing proprietary blood-based technologies to improve diagnosis and treatment of neurological disorders and early-stage cancer, today announced the appointment of DR Richard Batrla, as chief medical officer. 9 January 2025
Biotechnology
Cambridge, USA-based biotech Rectify Pharmaceuticals today announced the appointment of Bharat Reddy as chief business officer (CBO). 15 July 2024
Biotechnology
UK-based Mogrify, a regenerative medicine company developing a novel class of in vivo reprogramming therapies for diseases with high unmet clinical need, has announced the appointment of Jonathan Appleby as chief scientific officer (CSO). 15 July 2024
Biotechnology
Henry Pelish has continued his rise up the ranks at Nuvalent, a Boston-based biopharma focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. 11 July 2024
Biotechnology
CureLab Oncology has appointed Aubrey Galloway as chief medical officer. 11 July 2024
Pharmaceutical
US drugmaker AbbVie has announced that Roopal Thakkar, who currently serves as senior vice president, chief medical officer, global therapeutics, has been appointed to the position of executive vice president, research and development, and chief scientific officer (CSO). 10 July 2024
Biotechnology
USA-based drug conjugates (ADCs) developer Sutro Biopharma
has appointed Barbara Leyman, as chief business development officer, effective July 8, 2024. 10 July 2024
Biotechnology
Immunic, a US biotech developing a pipeline of orally-administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has appointed experienced biopharma executive Jason Tardio as chief operating officer and president. 9 July 2024
Pharmaceutical
US pharma giant Pfizer is launching the process to identify a successor for Mikael Dolsten. 9 July 2024
Biotechnology
Stalicla, a privately-held Swiss biotech developing precision medicine-based treatments for neurodevelopmental and neuropsychiatric disorders such as autism spectrum disorder, has named Purnanand Sarma as chair of its board of directors. 9 July 2024
Biotechnology
French immuno-oncology company ImCheck Therapeutics has appointed Stephan Braun as chief medical officer. 9 July 2024
Biotechnology
Privately-held UK biotech Curve Therapeutics today announced the appointment of Simon Jones to the posts of chief financial (CFO) and chief operating officer (COO) of the company. 9 July 2024
Biotechnology
Memo Therapeutics, a privately-held Swiss biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, has announced the appointment of Paul Carter as chair of the board of directors. 8 July 2024
Biotechnology
DNA specialist INOVIO has appointed Steven Egge as chief commercial officer. 4 July 2024
Biotechnology
Dutch life sciences venture capital firm Forbion has announced the hiring of Josh Brumm, former president and chief executive of Dyne Therapeutics, as a general partner. 1 July 2024
Biotechnology
US immunology focused biotech Zenas BioPharma says it has appointed Orlando Oliveira as its chief commercial officer (CCO). 1 July 2024
Pharmaceutical
Wolfgang Wienand today joined Swiss contract development and manufacturing organization (CDMO) Lonza as chief executive (CEO). 1 July 2024
Biotechnology
US biotech Arialys Therapeutics has appointed Peter Flynn as president and chief executive (CEO). 28 June 2024
Biotechnology
Release Therapeutics, Appointment, Chief executive,
Thomas Mehrling as CEO 27 June 2024
Biotechnology
French biotech MaaT Pharma has appointed Gianfranco Pittari as chief medical officer. 25 June 2024
Pharmaceutical
Audrey Duval Derveloy, currently president of Sanofi France, has been named executive vice president, global head of corporate affairs. 21 June 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze